Study shows elderly readily adapt to remote monitoring
MENDOTA HEIGHTS, Minn., and PHILADELPHIA Elderly people who rely on remote monitoring technology for security and independence adapt well to living with the technology and don’t see it as intrusive or impersonal, according to a report released Wednesday.
The survey, conducted at four locations within the NewCourtland Network, examined effectiveness of Healthsense’s eNeighbor remote monitoring technology and captured the perceptions of residents, family members and staff.
Participants in the survey agreed that the system makes them feel safer and more secure while allowing them to live independently for longer, witch exception to one of the people surveyed, who expressed concern about intrusiveness.
“We thought at first that adapting to the technology would be a major issue for our residents, but clearly it was not,” said NewCourtland vice president for housing and community-based services Kim Brooks. “The results of the survey demonstrate that even seniors with little or no prior exposure to this technology can readily adapt to it once they realize the improved quality of life it offers.”
The NewCourtland Network is a non-profit provider of community services, housing and nursing homes for more than 2,200 elderly people in Philadelphia.
Glue-like bacterial sugar could lead to vaccine
LONDON A study has found that when manipulated with chemicals, a sugar that drug-resistant bacteria secrete triggered an immune response in animals.
The study, presented last week at the Dublin, Ireland, meeting of the Society for General Microbiology used a glue-like sugar that bacteria produce to protect themselves from antibiotics called PNAG.
PNAG alone does not produce an immune response in most people and animals, but the researchers, from the Harvard Medical School, hope that formulations of it do.
FDA announces likely delay on Novo Nordisk diabetes drug
WASHINGTON The Food and Drug Administration has announced that it will be unable to meet the user fee deadline for a timely approval of Novo Nordisk’s drug liragludite.
The FDA will not be able to make an approvability decision until March 23 for the drug, a treatment for Type 2 diabetes. Novo Nordisk had submitted an approval application for the drug on May 23.
The standard review period for FDA action on approval applications is 10 months. Because the agency’s advisory committee meeting will take place shortly before March 23, however, its decision will probably be delayed by a further two months, the company said.